Stockreport

Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF See our latest analysis for Immuneering. Despite the strong clinical update, Immuneering's latest share price of $4.66 comes after a 30 day share price return of a 23 [Read more]